NXGLHealthcare · Medical Instruments & SuppliesNXGL Stock Forecast: NexGel, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering NexGel, Inc. hold a median 12-month price target of $2 — +372.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
NXGL stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores NexGel, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (96): Smaller than most of the companies we track.
Momentum (4): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own NexGel, Inc. — and when they’d sell — is the membership.
NXGL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NXGL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +372.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Mar 2026 | Maxim Group | Maintains | Buy | $6.00 → $2.00 |
| 25 Feb 2022 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NXGL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
NexGel, Inc. (NXGL) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −1.1×
- Price / sales
- 0.3×
- Price / book
- 0.9×
- EV / EBITDA
- −2.7×
Cheaper than 82% of US stocks
Cheaper than 88% of US stocks
Cheaper than 76% of US stocks
Cheaper than 75% of US stocks
- Revenue growth (YoY)
- −5.6%
- Earnings growth (YoY)
- −5.6%
- Gross margin
- 40.0%
- Operating margin
- −36.2%
- Net margin
- −28.5%
Higher than 20% of US stocks
Higher than 30% of US stocks
Higher than 51% of US stocks
Higher than 20% of US stocks
Higher than 14% of US stocks
- Return on equity
- −61.4%
- Return on assets
- −20.0%
- Dividend yield
- —
Higher than 19% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
NXGL vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NXGL appears on the weeks it earns a place.
Frequently asked questions about NXGL stock
What is the NXGL stock price forecast for 2026-2027?
The 1 Wall Street analysts covering NexGel, Inc. have a median 12-month price target of $2, with estimates ranging from $2 to $2. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is NXGL stock a buy right now?
Of the 1 analysts covering NexGel, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NexGel, Inc. 25 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank NXGL?
As at 1 Aug 2026, NexGel, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).
Will NXGL stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +372.6% from the last close, and Ticker Nerd's factor model ranks NexGel, Inc. 25 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the NXGL stock forecast for 2030?
No analyst covering NexGel, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NXGL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $2 over the next 12 months.
How has NXGL stock performed over the past year?
NexGel, Inc. returned -83.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does NexGel, Inc. do?
NexGel Inc. is a specialty healthcare company that manufactures and sells high water content, electron beam cross-linked aqueous polymer hydrogels and gels primarily for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States.
About NexGel, Inc.
NexGel Inc. is a specialty healthcare company that manufactures and sells high water content, electron beam cross-linked aqueous polymer hydrogels and gels primarily for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: NexGel, focused on producing ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, and CG labs. The company provides over-the-counter remedy solutions including blister and pain applications, alongside beauty and cosmetic solutions. NexGel Inc. also engages in contract manufacturing and maintains a portfolio of branded consumer products in health, wellness, and beauty categories. Recent initiatives include partnerships for launching enzyme supplements and acquisitions of international beauty brands to expand its consumer offerings. Additionally, it develops innovative products such as NEXDrape, an incise surgical drape for patients with impaired skin, and NEXDerm, an adhesive tape for securing medical devices. Founded in 2007 and headquartered in Langhorne, Pennsylvania, NexGel Inc. plays a key role in advancing hydrogel-based solutions across medical and personal care markets.
CEO Mr. Adam R. Levy · 19 employees · United States · https://nexgel.com